X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SKI-O-703 (cevidoplenib) is a SYK inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with immune thrombocytopenia.
Lead Product(s): Cevidoplenib
Therapeutic Area: Immunology Product Name: SKI-O-703
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, which is investigated for the treatment of alzheimer's disease.
Lead Product(s): ADEL-Y01
Therapeutic Area: Neurology Product Name: ADEL-Y01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ADEL Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, which is investigated for the treatment of alzheimer's disease.
Lead Product(s): ADEL-Y01
Therapeutic Area: Neurology Product Name: ADEL-Y01
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: ADEL Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Under the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, including BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST.
Lead Product(s): BEA-17
Therapeutic Area: Oncology Product Name: BEA-17
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Beactica
Deal Size: $178.0 million Upfront Cash: Undisclosed
Deal Type: Termination April 04, 2023
Details:
SKI-O-592 (cevidoplenib) binds to and inhibits SYK activity, blocking Fc receptor and BCR-mediated signaling in inflammatory cells. This leads to the inhibition of the related inflammatory responses and tissue damage. It is being developed for immune thrombocytopenia.
Lead Product(s): Cevidoplenib
Therapeutic Area: Immunology Product Name: SKI-O-592
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
